These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33402494)

  • 1. CD133 Expression Predicts Relapse in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemotherapy.
    Oi H; Okuyama T; Miyazaki S; Ono Y; Oya M
    In Vivo; 2021; 35(1):437-445. PubMed ID: 33402494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
    Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
    World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 4. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
    Sclafani F; Brown G; Cunningham D; Rao S; Tekkis P; Tait D; Morano F; Baratelli C; Kalaitzaki E; Rasheed S; Watkins D; Starling N; Wotherspoon A; Chau I
    Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indications for neoadjuvant treatment based on risk factors for poor prognosis before and after neoadjuvant chemotherapy alone in patients with locally advanced rectal cancer.
    Ogura A; Uehara K; Aiba T; Sando M; Tanaka A; Ohara N; Murata Y; Sato Y; Hattori N; Nakayama G; Ebata T; Kodera Y; Nagino M
    Eur J Surg Oncol; 2021 May; 47(5):1005-1011. PubMed ID: 33189492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy].
    Cai C; Wang J; Zhong Z; Dai Z; Wang Q; Dong W; Shi H; Liu Q; DU J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):36-43. PubMed ID: 28436629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 9. [Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
    Li D; Wu H; Feng R; Zhong D; Luo Y; Xiao Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):690-4. PubMed ID: 27353106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y; Brahmi SA; Afqir S
    Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of RAS/BRAF mutation status in locally advanced rectal cancer treated with preoperative chemotherapy.
    Oshiro T; Uehara K; Aiba T; Mukai T; Ebata T; Nagino M
    Int J Clin Oncol; 2018 Aug; 23(4):681-688. PubMed ID: 29478127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial.
    Tomida A; Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Okada Y; Kurumiya Y; Nakayama G; Nakamura M; Aiba T; Nagino M;
    Int J Clin Oncol; 2019 Apr; 24(4):403-410. PubMed ID: 30471067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
    Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH
    BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer.
    Zhang Y; Yan L; Wu Y; Xu M; Liu X; Guan G
    BMC Cancer; 2020 Sep; 20(1):854. PubMed ID: 32891131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
    Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
    Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
    Sun Y; Wu X; Zhang Y; Lin H; Lu X; Huang Y; Chi P
    Eur J Surg Oncol; 2019 Jul; 45(7):1225-1231. PubMed ID: 30879932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Fluoropyrimidine and Oxaliplatin-based Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.
    Okada Y; Ozawa T; Hayama T; Ohno K; Tsukamoto M; Fukushima Y; Shimada R; Nozawa K; Matsuda K; Hashiguchi Y
    In Vivo; 2021; 35(1):593-601. PubMed ID: 33402514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
    Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
    Sclafani F; Brown G; Cunningham D; Wotherspoon A; Tait D; Peckitt C; Evans J; Yu S; Sena Teixeira Mendes L; Tabernero J; Glimelius B; Cervantes A; Thomas J; Begum R; Oates J; Chau I
    Ann Oncol; 2016 Aug; 27(8):1557-65. PubMed ID: 27217542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is neoadjuvant chemoradiotherapy always necessary for mid/high local advanced rectal cancer: A comparative analysis after propensity score matching.
    Zhang Y; Sun Y; Xu Z; Chi P; Lu X
    Eur J Surg Oncol; 2017 Aug; 43(8):1440-1446. PubMed ID: 28502421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.